Cyclophilin D Modulates the Mitochondrial Acetylome

Tiffany Tuyen M. Nguyen¹, Renee Wong², Sara Menazza¹, Junhui Sun¹, Yong Chen³, Guanghui Wang³, Marjan Gucek³, Charles Steenbergen⁴, Michael N. Sack⁵, and Elizabeth Murphy¹

¹Systems Biology Center; ²Division of Cardiovascular Sciences; ³Proteomics Core Facility, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; ⁴Department of Pathology Johns Hopkins Medical Center, Baltimore, MD, and ; ⁵Center for Molecular Medicine, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, 20892.

Running title: Role of CypD in Mitochondrial Protein Acetylation

Subject codes:
[107] Biochemistry and metabolism
[130] Animal models of human disease
[137] Cell biology/structural biology

Address correspondence to:
Dr. Elizabeth Murphy
National Heart, Lung, and Blood Institute
National Institutes of Health
Building 10, Room 8N202
10 Center Drive
Bethesda, MD 20892
Tel: 301-496-5828
Fax: 301-402-0190
murphy1@mail.nih.gov

In August 2013, the average time from submission to first decision for all original research papers submitted to Circulation Research was 12.8 days.

DOI: 10.1161/CIRCRESAHA.113.301867
ABSTRACT

**Rationale:** Mice lacking cyclophilin D (CypD−/−), a mitochondrial chaperone protein, have altered cardiac metabolism. As acetylation has been shown to regulate metabolism, we tested whether changes in protein acetylation might play a role in these metabolic changes in CypD−/− hearts.

**Objective:** To test the hypothesis that loss of CypD alters the cardiac mitochondrial acetylome.

**Methods and Results:** To identify changes in lysine-acetylated proteins and map acetylation sites following ablation of CypD, we subjected tryptic digests of isolated cardiac mitochondria from WT and CypD−/− mice to immunoprecipitation using agarose beads coupled to anti-acetyl lysine antibodies followed by mass spectrometry. We used label-free analysis for the relative quantification of the 875 common peptides that were acetylated in WT and CypD−/− samples and found 11 peptides (10 proteins) decreased and 96 peptides (48 proteins) increased in the CypD−/− samples. We found increased acetylation of proteins in fatty acid oxidation and branched-chain amino acid metabolism. To evaluate whether this increase in acetylation might play a role in the inhibition of fatty acid oxidation that was previously reported in CypD−/− hearts, we measured the activity of L-3-hydroxyacyl-CoA dehydrogenase (LCHAD), which was acetylated in the CypD−/− hearts. Consistent with the hypothesis, LCHAD activity was inhibited by approximately 50% compared to the WT mitochondria.

**Conclusions:** These results implicate a role for CypD in modulating protein acetylation. Taken together, these results suggest that ablation of CypD leads to changes in the mitochondrial acetylome, which may contribute to altered mitochondrial metabolism in CypD−/− mice.

**Keywords:**
Cyclophilin D, acetylation, mitochondria, sirtuin 3 (SIRT3), cardiac metabolism, proteomics

**Nonstandard Abbreviations and Acronyms:**
- CsA: Cyclosporine A
- CypD: Cyclophilin D
- KO: knockout
- mPTP: mitochondrial permeability transition pore
- PTM: post-translational modification
- Sirtuin 3: SIRT3
- WT: wildtype
INTRODUCTION

Cyclophilin D (CypD) is a peptidyl prolyl cis-trans-isomerase, which functions as a mitochondrial protein chaperone and is therefore likely to have multiple targets. CypD is also known to be an activator of the mitochondrial permeability transition pore (mPTP). The mPTP is a non-selective pore in the inner mitochondrial membrane that is opened by high matrix calcium and/or reactive oxygen species (ROS)\(^1\). Sustained opening of the mPTP results in loss of membrane potential, uncoupling of oxidative phosphorylation, matrix swelling, ATP depletion, and increased production of reactive oxygen species, ultimately leading to cell death. The mPTP plays a critical role in mediating cell death during ischemia/reperfusion injury and inhibition of the mPTP is proposed to be the end-effector of cardioprotective signaling cascades\(^4\). In addition to sustained activation of the mPTP, which leads to cell death, the mPTP has been shown to open transiently. It has been proposed that transient opening of the mPTP can serve as a mitochondrial calcium release mechanism\(^1\).

Loss or inhibition of CypD has been shown to lead to an increase in mitochondrial calcium, which results in activation of mitochondrial NADH dehydrogenases such as pyruvate dehydrogenase and alterations in the ratio of carbohydrate to fatty acid oxidation\(^6\). Using both proteomic and metabolomic approaches, we previously found that mitochondria from CypD\(^{-/-}\) hearts have alterations in pyruvate and branched chain amino acid metabolism, as well as changes in levels of mitochondrial histone proteins\(^7\). Because acetylation has been shown to regulate mitochondrial metabolism, we consider that the metabolic changes observed with loss of CypD might be due to alterations in the mitochondrial acetylome. Protein acetylation is a reversible post-translational modification (PTM), which adds an acetyl moiety to the epsilon-amino group of lysine residues\(^8\). Protein acetylation has been shown to play a key role in histone modifications and is well known to influence changes in gene expression\(^12\), but much less is known about its role in non-nuclear protein acetylation and cellular regulation. In particular, emerging data indicate that many proteins within the mitochondria are reversibly acetylated\(^13\). The acetylation of many metabolic enzymes has been shown in liver and yeast, but there is little comprehensive data in heart. We therefore examined the effect of loss of CypD on cardiac mitochondrial protein acetylation. In the present study, we found that loss of CypD resulted in an increase in acetylation of many mitochondrial proteins in a profile consistent with cardiac metabolic remodeling in CypD\(^{-/-}\) mice.

METHODS

Please see the Online Supplement available at [http://circres.ahajournals.com](http://circres.ahajournals.com) for detailed materials and methods related to this study.

**Animals.**
Adult male 12-16 week old WT and CypD\(^{-/-}\) mice, obtained from Dr. Jeffery Molkentin (Cincinnati Children’s Hospital Medical Center), were studied. All animals were treated and cared for in accordance with the Guide for the Care and Use of Laboratory Animals [National Institutes of Health (NIH), Revised 2011], and protocols were approved by the Institutional Animal Care and Use Committee.

**Mitochondria isolation.**
Mitochondria were isolated by differential centrifugation according to standard procedures\(^15\).

**Immunoprecipitation (IP) for acetylated proteins.**
Isolated mitochondria (500 \(\mu\)g) were subjected to immunoprecipitation followed by Western blot analyses as previously described\(^16\) using anti-GRP75, anti-F\(_{1}F_{0}\) ATP synthase subunit A (ATPA), anti-pyruvate dehydrogenase E1 component subunit alpha (ODPA) antibodies.
**Western blot.**

Equivalent amounts of protein (20-40 µg) from each sample were separated on NuPAGE 4–12% Bis-Tris gels (Invitrogen, Carlsbad, CA) and transferred to nitrocellulose membranes. Gel transfer efficiency and equal loading were verified using reversible Ponceau S staining. The resulting blots were probed with anti-acetylated lysine antibody (Cell Signaling, Danvers, MA), anti-GCN5L1, anti-SIRT3, anti-VDAC-1 (Santa Cruz Biotechnology), anti F1Fo ATP synthase α subunit, or anti Cyclophilin D antibody (Mitosciences, Eugene, Oregon).

**Affinity purification of lysine-acetylated peptides for mass spectrometry.**

Isolated mitochondrial pellets (1 mg) were subjected to immunoprecipitation as previously described to identify lysine-acetylated peptides by mass spectrometry. The LCMS data were searched against the Swiss Prot database, taxonomy Musculus (mouse) using Mascot server (Matrix Science, London, UK; version 2.3). Relative quantification of acetylated peptides were performed using QUOIL (QUantification withOut Isotope Labeling), an in-house software program designed as a label-free approach to peptide quantification by LC-MS/MS.

**SIRT3 activity.**

Mitochondria were isolated from WT and CypD−/− mouse hearts. SIRT3 activity was measured using SIRT3 Direct Fluorescent Screening Assay Kit (Cayman Chemical, Ann Arbor, MI) in the presence and absence of nicotinamide (NAM).

**Langendorff heart perfusion and protocol.**

Mouse hearts were subjected to Langendorff perfusion as previously described.

**Myocyte isolation.**

Adult mouse ventricular myocytes were isolated by collagenase digestion as described previously and attached to matrigel-coated coverslips for 30 min in a 5% CO2 incubator at 37°C in medium supplemented with 5 mmol/L creatine, 2 mmol/L L-carnitine, 5 mmol/L taurine, 2.5 mmol/L sodium pyruvate, 26 mmol/L NaHCO3, 100 U/mL penicillin, and 100 µg/mL streptomycin.

**Mitochondrial NADH measurement.**

Myocytes were mounted on the stage of a fluorescence microscope (Nikon Diaphot) with a 20× objective and superfused with Tyrode’s solution (25°C) containing (mmol/L): 140 NaCl, 4 KCl, 1 MgCl2, 5 HEPES, and 10 D-glucose (pH 7.4). The endogenous mitochondrial NADH autofluorescence was excited at λ_{exc} = 340 nm (band pass filter) and its emission recorded at λ_{em} = 415 nm (long pass filter) into a QuantEM 512 SC electron-multiplying charge-coupled device (CCD) camera (Photometrics, Tucson, AZ). NADH levels were expressed as a percent of the reduced NADH/NAD+ pool, which was calibrated by applying 4 mmol/L NaCN (100%) and 5 µmol/L carbonyl cyanide 3-chlorophenyl hydrazone (CCCP) (0%) for each experiment.

**Mitochondrial swelling and calcium retention capacity assays.**

Mitochondrial permeability transition pore opening in isolated heart mitochondria from WT and CypD−/− mouse hearts was assessed using the calcium retention capacity (CRC) and Ca^{2+}-induced swelling assays. CRC was assessed using 10 µM fluorescent Ca^{2+} indicator Calcium Green-5N (Molecular Probes, Eugene, OR) with the addition of 10 µM Ca^{2+} pulses to induce mPTP opening. Ca^{2+}-induced swelling assay was measured spectrophotometrically as a decrease in absorbance at 540 nm after pore opening that was induced by 250 µM of CaCl2. Both assays were assessed in the presence and absence of 200 nM cyclosporine A (CsA), a known CypD and mPTP inhibitor.
Trifunctional protein enzyme alpha subunit activity measurements.
The activity of the L-3-hydroxyacyl-CoA dehydrogenase (LCHAD) was measured in isolated mitochondria from WT and CypD mouse hearts. After mitochondria isolation, the pellet was suspended in 25 mmol/L potassium phosphate, 50 mmole/L MOPS, 0.2 mmol/L EDTA, pH 8.0. The mitochondria suspensions were freeze-thawed 3X and sonicated on ice for 3X10s with a 1-min interval in between. Triton X-100 was then added to the suspensions to give a Triton X-100 to protein ratio of 1:1. After incubation on ice for 30 min, the extracted were centrifuged at 11600g for 10 min. Enzyme activities were then measured in the supernatant at 37°C in the presence of 100 μmole/L NADH and 100 μmole/L acetoacetyl CoA. The LCHAD activity was calculated as the rate of NADH oxidized per min/mg protein.

Statistical analysis.
All data were expressed as mean ± standard error. The student’s 2-sample t-test or one-way ANOVA with Bonferroni’s post hoc analyses were used for comparison of differences between groups and a p-value ≤ 0.05 was considered to be significant.

RESULTS
Alterations in the mitochondrial acetylation profile following loss of CypD.
We previously found that CypD— hearts have increased pyruvate dehydrogenase (PDH) activity and a reduction in fatty acid oxidation relative to glucose oxidation. We also found changes in branched-chain amino acid metabolism in CypD— hearts. As mitochondrial acetylation has emerged as a key regulator of mitochondrial fatty acid and branched-chain amino acid metabolisms, we tested whether CypD— hearts might have altered mitochondrial acetylation. Acetylation/deacetylation of protein lysine residues has emerged as an important PTM for dynamic regulation of many proteins. We initially examined changes in lysine-acetylated proteins following the ablation of CypD. As shown in Figure 1 (A-B), Western blot analysis shows that acetylation levels were increased by 45% ± 12% in CypD— mitochondria.

The acetylome has been compiled for yeast, mouse, and rat liver, but the cardiac mitochondrial acetylome has not been well-defined. We therefore decided to define the cardiac mitochondrial acetylome including sites of acetylation at baseline in WT hearts. We accomplished this by subjecting tryptic digests of isolated cardiac mitochondria from WT mice to immunoprecipitation using anti-acetyl lysine antibody coupled to agarose beads followed by mass spectrometry. In WT mitochondria, we found 198 acetylated proteins (with 864 peptides) at baseline (Figure 2A and Online Table I, n=3 biological replicates). As reported in Online Table I, 57 of these proteins were from the electron transport complexes I to V (258 acetylated peptides). More than 50% of the electron transport complexes were found to be acetylated at baseline. We also found that all of the TCA cycle proteins as well as a large number of enzyme involved in fatty acid oxidation were acetylated. We also found 11 mitochondrial carrier proteins acetylated, including regulators (CCDC90A and B) of the recently described mitochondrial Ca2+ uniporter (MCU) and mitochondrial pyruvate carrier 2 (Brain protein 44). Of interest, we found CypD is acetylated consistent with previous data. Thus, most of the enzymes involved in cardiac mitochondrial metabolism and bioenergetics are acetylated at baseline.

As shown in Figure 1A, there is an increase in global acetylation in mitochondria isolated from mice lacking CypD. We therefore compared the acetylome of WT mitochondria to that of CypD—. We manually inspected all the spectra of identified acetylated peptides using Scaffold PTM software in conjunction with the Proteome Discover software. As shown in Figure 2A, in the CypD— mitochondria we identified 955 acetylated peptides (from 219 proteins) with 875 acetylated peptides common between
WT and CypD−/− samples (see Online Table II for a complete list of acetylated proteins and peptides). Using the criteria defined in the legend of Figure 2A, we found 45 peptides that were only acetylated in WT (Online Table III), and 35 peptides that were acetylated only in the CypD−/− mitochondria (Online Table IV). We concentrated our analysis on the 875 acetylated peptides that were detected in both WT and CypD−/− samples. A label-free analysis program for relative quantification of the common acetylated peptides between WT and CypD−/− samples was used and representative ion chromatographs are shown (Figure 2B, C, and D). We found 11 peptides (from 10 proteins) decreased in CypD−/− mitochondria by at least 20% or greater with a p <0.05 (Table 2). Using similar criteria, we found 96 peptides from 48 proteins that showed an increase acetylation in the CypD−/− mitochondria (Online Table V). We confirmed the increase in acetylation of several proteins by subsequent immunoprecipitation of acetylated proteins followed by immunoblot analysis with antibodies recognizing GRP75, F1Fo ATP synthase alpha subunit, and pyruvate dehydrogenase E1 component alpha subunit (Figure 1C). The increase or decrease in acetylation noted in Figure 2A could be due to a change in protein level in the CypD−/− hearts. In a previous study, we examined changes in protein levels in CypD−/− hearts7. We compared the changes in protein levels in CypD−/− heart to changes in acetylation. Two of the 10 proteins (VDAC3 and DHSA) that showed a decrease in acetylation (Table 2) had reduced expression levels in the CypD−/− hearts. Thus, the decrease in acetylation in these proteins is likely due to decreased protein level. Of the 48 proteins that showed an increase in acetylation (Online Table V), only 3 proteins (PRDX5, ODPA and NDUA5) showed an elevated protein level. Therefore, the increase in protein acetylation for the vast majority of proteins cannot be attributed to an increase in protein expression. A change in acetylation has also been suggested to alter protein stability. Only 3 proteins increased in both acetylation and protein levels (PRDX5, ODPA and NDUA5), and these proteins are potential candidates whereby acetylation may increase their stability22. Of the 30 proteins that showed a decrease in protein level in CypD−/− hearts, only 2 showed an increase in acetylation (M2OM and NDUV1). Thus acetylation does not appear to have a dramatic effect on protein expression in the adult myocardium.

Although acetylation does not have a large impact on protein stability, it could have a major impact on enzyme activity and metabolism. The reduction in fatty acid oxidation observed previously in the CypD−/− hearts6 is entirely consistent with the changes in acetylation observed in the CypD−/− hearts. Increased acetylation has been shown previously to inhibit fatty acid oxidation23, 24. Consistent with the reduction in fatty acid oxidation in the CypD−/− hearts, we saw an increase in the acetylation of key enzymes involved in fatty acid oxidation. We found an increase in acetylation in both subunits of trifunctional enzyme (ECHB and ECHB), long-chain specific acyl-CoA dehydrogenase (ACADL), 2,4-dienoyl-CoA reductase (DECR), 3-ketoacyl-CoA thiolase (THIM), and enoyl-CoA delta isomerase 1 (ECI1). To test the functional effect of acetylation on enzyme activity, we measured the L-3-hydroxyacyl-CoA dehydrogenase (LCHAD) activity of the trifunctional protein (TFP) alpha subunit, an enzyme involved in fatty acid oxidation, which showed an increase in acetylation in the CypD−/− mitochondria. We found that the LCHAD activity was inhibited by approximately 50% in the CypD−/− mitochondria as compared to the WT mitochondria (Figure 3). To further evaluate whether an increase in acetylation results in a decrease in the LCHAD activity, we preincubated the WT sonicated mitochondria with 100 μM acetyl-CoA (confirming an increase in acetylation of LCHAD by Western blot analysis). Consistent with the hypothesis, with the acetyl CoA treatment, the LCHAD activity was inhibited similarly to the CypD−/− group. To identify the pathways affected by the increase in protein acetylation in the CypD−/− hearts, we performed pathway analysis using Ingenuity software. The acetylated peptides comprise pathways involved in oxidative phosphorylation, mitochondrial dysfunction, butanoate metabolism, pyruvate metabolism, and branched chain amino acid metabolism (Online Figure I).

We examined the mechanisms responsible for changes in the mitochondrial acetylome in the CypD−/− mice. A recent study has shown, in an in vitro assay, that increasing NADH while NAD+ is held constant leads to a significant decrease in SIRT3 activity25. As the NADH/NAD+ ratio can change during isolation of mitochondria, we measured the endogenous NADH fluorescence in WT and CypD−/− cardiomyocytes.
Baseline NADH levels were increased by ~80% in CypD⁻/⁻ hearts relative to WT (29.44 ± 2.63 vs. 16.20 ± 2.86 % of fully-reduced NADH) (Figure 4A). Western blot analysis showed no difference in either the mitochondrial acetyl transferase, GCN5L1 (Figure 4B) or deacetylases, SIRT3 (Figure 4C), SIRT4 (Figure 4D) or SIRT5 (Figure 4E) between WT and CypD⁻/⁻ mitochondria, which would support a primary role for an increase in NADH in the increase in acetylation. Finally, there was no difference in SIRT3 activity between WT and CypD⁻/⁻ mitochondria (Figure 3F) measured under conditions where the NAD and NADH were fixed in the assay.

To gain additional insight into the mechanism by which loss of CypD leads to an increase in acetylation, we determined whether the peptides acetylated in CypD⁻/⁻ hearts were SIRT3 substrates. To accomplish this, we compared the peptides showing an increase in acetylation following ablation of SIRT3 to the list of acetylated peptides increased in hearts lacking CypD. We found 151 peptides that exhibited an increase in acetylation in SIRT3⁻/⁻ hearts compared to WT littermates; we defined these peptides as potential SIRT3 substrates (Online Table VI). Of interest, CypD itself is a SIRT3 substrate. If we compare these 151 peptides to the 96 peptide that exhibited an increase in acetylation in the CypD⁻/⁻ hearts, we found only 19 common peptides that are potential SIRT3 substrates (Online Table V, bolded).

CypD⁻/⁻ hearts have reduced I/R injury⁴, and this raises the question as to whether the increase in mitochondrial acetylation plays a role in cardioprotection. Mitochondria isolated from CypD⁻/⁻ mice have been shown to be more resistant to mPTP opening than WT mice⁴. To address whether an increase in mitochondrial acetylation reduces mPTP opening, we used SIRT3⁻/⁻ mice. These mice have been shown (and we confirmed) to have increased protein acetylation²⁶. Consistent with previous studies²⁷, we found no difference in mPTP opening between the WT and SIRT3⁻/⁻ mitochondria isolated from 3 month old mice (Figure 5). The mPTP opening was sensitive to CsA, a known mPTP inhibitor. These data suggest that an increase in mitochondrial acetylation per se is not sufficient to alter mPTP.

**DISCUSSION**

A number of studies have shown that acetylation regulates metabolic enzymes by multiple mechanisms, including enzymatic activation¹⁰, inhibition²⁸, or protein stability²². A recent proteomics study by Kim et al. revealed that over 20% of liver mitochondrial proteins and enzymes are acetylated and that changes occur in acetylation status in response to acute fasting¹³. Previous studies have identified several acetylated proteins in cardiac mitochondria²⁹; however, this is the first study to evaluate large scale acetylation in cardiac mitochondria. In this study, we identified over 200 cardiac mitochondrial proteins that are acetylated under basal conditions. We found that more than 50% of the electron transport complex proteins are acetylated at baseline. We also found baseline acetylation of TCA and fatty oxidation enzymes.

This study demonstrates that loss of CypD results in an increase in acetylation. We found an increase in acetylation of many enzymes involved in fatty acid oxidation, and previous studies have reported that increased acetylation of specific fatty acid oxidation enzymes leads to their inhibition²³, ²⁴. We provide new data showing that acetylation of LCHAD results in its inhibition.

What is the mechanism responsible for the increase in acetylation in the CypD⁻/⁻ hearts? Reversible lysine acetylation is regulated by opposing activities of protein acetyltransferases and deacetylases. We found no increase in the protein level of the recently described mitochondrial acetyltransferase (GCN5L1)³⁰. We also found no change in the levels of the three mitochondrial deacetylases, SIRT3, SIRT4 and SIRT5. We also found no change in activity of SIRT3. The data are most consistent with the hypothesis that loss of CypD leads to an increase in NADH/NAD⁺ resulting in inhibition of deacetylase(s).
and an increase in protein acetylation (Online Figure II). Previous studies have suggested that a change in the NADH/NAD⁺ ratio can alter the activity of sirtuins²⁵,³¹-³³. A change in NADH/NAD⁺ would not carry-over in an assay of SIRT from mitochondria, in which the NAD⁺/NADH level is set as part of the assay. It is likely that this increase in NADH/NAD⁺ activates all mitochondrial sirtuins. This would be consistent with our data showing that CypD⁻/- hearts exhibited acetylation of many proteins that are not SIRT3 dependent substrates, as determined either in this study (Online Table V) or previous studies³⁴-³⁷. The current consensus (mostly obtained from data in liver) is that SIRT3 is the primary mitochondrial deacetylase²⁶. SIRT4 and SIRT5 have been shown to exhibit ADP-ribosyltransferase and deacetylase activity, respectively²⁶. However, there are data suggesting that SIRT4³⁸ and SIRT5²⁵ can also contribute to mitochondrial deacetylation.

It is well established that CypD⁻/- mitochondria have a decreased susceptibility to mPTP opening. As suggested in online Figure II, we propose that inhibition of transient opening of the mPTP leads to the increase in Ca²⁺, increased PDH activity, and ultimately, the increase in acetylation. The increase in acetylation per se does not appear to alter mPTP, although acetylation of a specific protein could be involved in regulation. Sinclair et al. reported that mitochondria from SIRT3⁻/- hearts have an increase in mPTP when measured at 18 months of age, but not at 3 or 6 months of age. They attributed the increase in mPTP at 18 months to an increase in acetylation of CypD²⁷. In SIRT3⁻/- heart mitochondria, we find a general increase in acetylation and a specific increase in the acetylation of CypD at 3 months of age, but we find no change in mPTP, which is consistent with the study of Sinclair’s group²⁷. The increase in mPTP observed at 18 months in the SIRT3⁻/- hearts could be due to metabolic changes that are known to occur in these mice rather than a direct effect of acetylation.

In summary, this study provides insights into changes in the cardiac mitochondrial acetylome occurring with loss of CypD and loss of SIRT3. Loss of CypD leads to an increase in protein acetylation which could account for the metabolic changes previously reported in these mice⁶.

ACKNOWLEDGEMENTS
We thank Drs. Marcia Haigis and Gaëlle Laurent from Harvard Medical School for kindly providing the SIRT4 antibody.

SOURCES OF FUNDING
This work was supported by the National Heart, Lung, and Blood Institute, National Institutes of Health intramural program.

DISCLOSURES
None.

REFERENCES


FIGURE LEGENDS

Figure 1. Increase in acetylation in isolated CypD−/− mitochondria. A) WT and CypD−/− mouse hearts were perfused for 5 min and mitochondria were isolated as described in the Methods section. Samples were analyzed by Western blot analysis using anti-acetylated lysine, anti-F1Fo ATP synthase β-subunit (as a loading control), and anti-Cyclophilin D. B) Mean densitometry data from 3 individual experiments. C) Mitochondria from WT and CypD−/− mouse hearts were subjected to immunoprecipitation using anti-acetyl lysine antibody followed by Western blot using anti-GRP75, anti-F1Fo ATP synthase subunit A (ATPA), anti-pyruvate dehydrogenase E1 component subunit alpha (ODPA) antibodies. The input bands reflect the protein level in the homogenate prior to IP and show no significant change in protein expression of GRP75, ATPA, or ODPA between wild-type and CypD−/− hearts.* p<0.05 compared with WT.

Figure 2. Mitochondrial acetylation following ablation of CypD. A) Acetylated peptides were identified using mass spectrometry as discussed in the Methods section. We manually inspected all the spectra of identified acetylated peptides using Scaffold PTM software in conjunction with the Proteome Discover software. This experiment was performed with 3 biological replicates in each group. To be considered as a common peptide or protein present, it must be present in at least 2 out of 3 replicates in one group and at least 1 out of 3 replicates in the other group (e.g., a peptide is present in 2 out of 3 WT samples, and in 1 out of 3 CypD−/− samples). To be included in the WT only group, a peptide/protein must be present in 2 out of 3 replicates in the WT samples and not present in any of the CypD−/− samples. To be included in the CypD−/− only group, a peptide/protein must be present in 2 out of 3 replicates in the CypD−/− samples and not present in any of the WT. B) Extracted ion chromatography of peptide DDNGkPYVLPSVR from AATM of WT and CypD−/− samples for a peptide that show no change in acetylation between samples. C) Extracted ion chromatography of peptide IAkDEGANAFFK from ADT1 (P48962) ADP/ATP translocase 1 of WT and CypD−/− samples for a peptide that show an increase in acetylation following loss of CypD. D) Extracted ion chromatography of YkWcEYGLTFTEK from VDAC2_MOUSE (Q60930) Voltage-dependent anion-selective channel protein 2 of WT and CypD−/− samples for a peptide that show a decrease in acetylation following loss of CypD.

Figure 3. Decrease in activity of L-3-hydroxyacyl-CoA dehydrogenase (LCHAD) in CypD−/− mitochondria. Mitochondria were isolated from WT and CypD−/− mouse hearts and LCHAD activity was measured. *p<0.05 vs. WT.

Figure 4. Increased in NADH/NAD+ levels following ablation of CypD. Measurement of baseline NADH/NAD+ in isolated cardiac myocytes, normalized with NaCN to give the 100% value and CCP to give 0% value (panel A). Mitochondria were isolated from WT and CypD−/− mouse hearts and samples were analyzed by Western blot analysis using anti-GCN5L1 (panel B), anti-SIRT3 (panel C), anti-SIRT4 (panel D) or anti-SIRT5 (panel E). Mean densitometry data from experiments are shown in the right. SIRT3 activity was measured using SIRT3 Direct Fluorescent Screening Assay Kit (Cayman Chemical, Ann Arbor, MI) in the presence and absence of nicotinamide (NAM) (panel F). *p<0.05 vs. WT or Con.

Figure 5. Hyperacetylation does not affect mPTP opening in SIRT3−/− mitochondria. Mitochondria were isolated from WT and SIRT3−/− mouse hearts. Mitochondrial permeability transition pore opening in isolated heart mitochondria from WT and SIRT3−/− mouse hearts was assessed using the calcium retention capacity assay (CRC) (Panel A) and Ca2+-induced swelling assay (Panel B). CRC was assessed using 10 μM fluorescent Ca2+ indicator Calcium Green-5N (Molecular Probes, Eugene, OR) with the addition of Ca2+ pulses to induce mPTP opening in the presence and absence of 200 nM cyclosporine A (CsA), a known mPTP inhibitor. * p<0.05 compared with CsA in each group.
<table>
<thead>
<tr>
<th>#</th>
<th>Accession</th>
<th>Protein ID</th>
<th>Protein Name</th>
<th># of acetylated peptides</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>AT5F1</td>
<td>Q9CQQ7</td>
<td>ATP synthase subunit b</td>
<td>9</td>
</tr>
<tr>
<td>2</td>
<td>ATP5E</td>
<td>P56382</td>
<td>ATP synthase subunit epsilon</td>
<td>4</td>
</tr>
<tr>
<td>3</td>
<td>ATP5H</td>
<td>Q9DCX2</td>
<td>ATP synthase subunit d</td>
<td>15</td>
</tr>
<tr>
<td>4</td>
<td>ATP5I</td>
<td>Q06185</td>
<td>ATP synthase subunit e</td>
<td>1</td>
</tr>
<tr>
<td>5</td>
<td>ATP5J</td>
<td>P97450</td>
<td>ATP synthase-coupling factor 6</td>
<td>7</td>
</tr>
<tr>
<td>6</td>
<td>ATP5L</td>
<td>Q9CPQ8</td>
<td>ATP synthase subunit g</td>
<td>5</td>
</tr>
<tr>
<td>7</td>
<td>ATP8</td>
<td>P03930</td>
<td>ATP synthase protein 8</td>
<td>3</td>
</tr>
<tr>
<td>8</td>
<td>ATPA</td>
<td>Q03265</td>
<td>ATP synthase subunit alpha</td>
<td>16</td>
</tr>
<tr>
<td>9</td>
<td>ATPB</td>
<td>P56480</td>
<td>ATP synthase subunit beta</td>
<td>7</td>
</tr>
<tr>
<td>10</td>
<td>ATPD</td>
<td>Q9D3D9</td>
<td>ATP synthase subunit delta</td>
<td>2</td>
</tr>
<tr>
<td>11</td>
<td>ATPG</td>
<td>Q91VR2</td>
<td>ATP synthase subunit gamma</td>
<td>7</td>
</tr>
<tr>
<td>12</td>
<td>ATPK</td>
<td>P56135</td>
<td>ATP synthase subunit f</td>
<td>4</td>
</tr>
<tr>
<td>13</td>
<td>ATPO</td>
<td>Q9DB20</td>
<td>ATP synthase subunit O</td>
<td>13</td>
</tr>
<tr>
<td>14</td>
<td>COX17</td>
<td>P56394</td>
<td>Cytochrome c oxidase copper chaperone</td>
<td>2</td>
</tr>
<tr>
<td>15</td>
<td>COX41</td>
<td>P19783</td>
<td>Cytochrome c oxidase subunit 4 isoform 1</td>
<td>4</td>
</tr>
<tr>
<td>16</td>
<td>COX5A</td>
<td>P12787</td>
<td>Cytochrome c oxidase subunit 5A</td>
<td>3</td>
</tr>
<tr>
<td>17</td>
<td>COX5B</td>
<td>P19536</td>
<td>Cytochrome c oxidase subunit 5B</td>
<td>5</td>
</tr>
<tr>
<td>18</td>
<td>COX6C</td>
<td>Q9CPQ1</td>
<td>Cytochrome c oxidase subunit 6C</td>
<td>3</td>
</tr>
<tr>
<td>19</td>
<td>COX7C</td>
<td>P17665</td>
<td>Cytochrome c oxidase subunit 7C</td>
<td>2</td>
</tr>
<tr>
<td>20</td>
<td>CX6B1</td>
<td>P56391</td>
<td>Cytochrome c oxidase subunit 6B1</td>
<td>1</td>
</tr>
<tr>
<td>21</td>
<td>CX7A1</td>
<td>P56392</td>
<td>Cytochrome c oxidase subunit 7A1</td>
<td>1</td>
</tr>
<tr>
<td>22</td>
<td>CY1</td>
<td>Q9D0M3</td>
<td>Cytochrome c1, heme protein</td>
<td>3</td>
</tr>
<tr>
<td>23</td>
<td>CYC</td>
<td>P62897</td>
<td>Cytochrome c, somatic</td>
<td>4</td>
</tr>
<tr>
<td>24</td>
<td>DHSA</td>
<td>Q8K2B3</td>
<td>Succinate dehydrogenase [ubiquinone] flavoprotein subunit</td>
<td>16</td>
</tr>
<tr>
<td>25</td>
<td>DSHB</td>
<td>Q9CQA3</td>
<td>Succinate dehydrogenase [ubiquinone] iron-sulfur subunit</td>
<td>4</td>
</tr>
<tr>
<td>26</td>
<td>ETFA</td>
<td>Q99LC5</td>
<td>Electron transfer flavoprotein subunit alpha</td>
<td>10</td>
</tr>
<tr>
<td>27</td>
<td>ETFB</td>
<td>Q9DCW4</td>
<td>Electron transfer flavoprotein subunit beta</td>
<td>10</td>
</tr>
<tr>
<td>28</td>
<td>ETFD</td>
<td>Q921G7</td>
<td>Electron transfer flavoprotein-ubiquinone oxidoreductase</td>
<td>6</td>
</tr>
<tr>
<td>29</td>
<td>NDUA2</td>
<td>Q9CQ75</td>
<td>NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2</td>
<td>3</td>
</tr>
<tr>
<td>30</td>
<td>NDUA4</td>
<td>Q62425</td>
<td>NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4</td>
<td>2</td>
</tr>
<tr>
<td>31</td>
<td>NDUA5</td>
<td>Q9CPP6</td>
<td>NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5</td>
<td>6</td>
</tr>
<tr>
<td>32</td>
<td>NDUA6</td>
<td>Q9CQZ5</td>
<td>NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 6</td>
<td>1</td>
</tr>
<tr>
<td>33</td>
<td>NDUA7</td>
<td>Q9Z1P6</td>
<td>NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 7</td>
<td>2</td>
</tr>
<tr>
<td>34</td>
<td>NDUA8</td>
<td>Q9DCJ5</td>
<td>NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8</td>
<td>3</td>
</tr>
<tr>
<td>35</td>
<td>NDUA9</td>
<td>Q9DC69</td>
<td>NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9</td>
<td>3</td>
</tr>
<tr>
<td>36</td>
<td>NDUAA</td>
<td>Q99LC3</td>
<td>NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10</td>
<td>6</td>
</tr>
</tbody>
</table>
List of electron transport chain complexes from common acetylated proteins in WTs were identified by LC-MS/MS. Accession numbers and Protein ID are from the SWISSPROT/Uniprot database.

<table>
<thead>
<tr>
<th>Accession</th>
<th>Name Description</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q9ERS2</td>
<td>NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13</td>
<td>2</td>
</tr>
<tr>
<td>Q9CQZ6</td>
<td>NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 3</td>
<td>2</td>
</tr>
<tr>
<td>Q9CQC7</td>
<td>NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4</td>
<td>2</td>
</tr>
<tr>
<td>Q9CQH3</td>
<td>NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 5</td>
<td>2</td>
</tr>
<tr>
<td>Q3UIU2</td>
<td>NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 6</td>
<td>1</td>
</tr>
<tr>
<td>Q9D6J5</td>
<td>NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8</td>
<td>1</td>
</tr>
<tr>
<td>Q9CQJ8</td>
<td>NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9</td>
<td>2</td>
</tr>
<tr>
<td>Q9DC99</td>
<td>NADH-ubiquinone oxidoreductase 75 kDa subunit 8</td>
<td>1</td>
</tr>
<tr>
<td>Q91VD9</td>
<td>NADH dehydrogenase [ubiquinone] iron-sulfur protein 3</td>
<td>2</td>
</tr>
<tr>
<td>P52503</td>
<td>NADH dehydrogenase [ubiquinone] iron-sulfur protein 6</td>
<td>2</td>
</tr>
<tr>
<td>Q9DC70</td>
<td>NADH dehydrogenase [ubiquinone] iron-sulfur protein 7</td>
<td>1</td>
</tr>
<tr>
<td>Q8K3J1</td>
<td>NADH dehydrogenase [ubiquinone] iron-sulfur protein 8</td>
<td>2</td>
</tr>
<tr>
<td>Q91YT0</td>
<td>NADH dehydrogenase [ubiquinone] flavoprotein 1</td>
<td>9</td>
</tr>
<tr>
<td>Q9D6J6</td>
<td>NADH dehydrogenase [ubiquinone] flavoprotein 2</td>
<td>2</td>
</tr>
<tr>
<td>Q9CZ13</td>
<td>Cytochrome b-c1 complex subunit 1</td>
<td>8</td>
</tr>
<tr>
<td>Q9DB77</td>
<td>Cytochrome b-c1 complex subunit 2</td>
<td>6</td>
</tr>
<tr>
<td>P99028</td>
<td>Cytochrome b-c1 complex subunit 6</td>
<td>2</td>
</tr>
<tr>
<td>Q9D855</td>
<td>Cytochrome b-c1 complex subunit 7</td>
<td>7</td>
</tr>
<tr>
<td>Q9CQ69</td>
<td>Cytochrome b-c1 complex subunit 8</td>
<td>2</td>
</tr>
<tr>
<td>Q9CR68</td>
<td>Cytochrome b-c1 complex subunit Rieske</td>
<td>2</td>
</tr>
</tbody>
</table>
Table 2. Acetylated proteins with decreased acetylation in the CypD<sup>+<sup> mitochondria.

<table>
<thead>
<tr>
<th>#</th>
<th>Protein</th>
<th>Peptide</th>
<th>WT</th>
<th>SE</th>
<th>KO</th>
<th>SE</th>
<th>KO/WT</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>ADT1_MOUSE (P48962) ADP/ATP translocase</td>
<td>gDQALSFL&lt;sub&gt;k&lt;/sub&gt;DFLAGGIAAAVSK</td>
<td>0.978</td>
<td>0.022</td>
<td>0.603</td>
<td>0.014</td>
<td>0.616</td>
<td>0.00</td>
</tr>
<tr>
<td>2</td>
<td>ANXA2_MOUSE (P07356) Annexin A2</td>
<td>SVcHLQ&lt;sub&gt;k&lt;/sub&gt;VF &lt;sub&gt;ER&lt;/sub&gt;</td>
<td>0.910</td>
<td>0.092</td>
<td>0.565</td>
<td>0.021</td>
<td>0.621</td>
<td>0.02</td>
</tr>
<tr>
<td>3</td>
<td>CISY_MOUSE (Q9CZU6) Citrate synthase</td>
<td>SMSTDGLM&lt;sub&gt;k&lt;/sub&gt;FV&lt;sub&gt;D&lt;/sub&gt;S&lt;sub&gt;K&lt;/sub&gt;</td>
<td>0.973</td>
<td>0.020</td>
<td>0.612</td>
<td>0.018</td>
<td>0.629</td>
<td>0.00</td>
</tr>
<tr>
<td>4</td>
<td>DHSA_MOUSE (Q8K2B3) Succinate dehydrogenase [ubiquinone] flavoprotein subunit</td>
<td>AAFGLSEAGFNTAcLT&lt;sub&gt;k&lt;/sub&gt;LFPTR</td>
<td>0.965</td>
<td>0.128</td>
<td>0.372</td>
<td>0.145</td>
<td>0.386</td>
<td>0.04</td>
</tr>
<tr>
<td>5</td>
<td>KCRS_MOUSE (Q6P8J7) Creatine kinase S-type</td>
<td>YYLSEMTEQDQQ&lt;sub&gt;R&lt;/sub&gt;</td>
<td>0.950</td>
<td>0.116</td>
<td>0.480</td>
<td>0.018</td>
<td>0.505</td>
<td>0.02</td>
</tr>
<tr>
<td>6</td>
<td>SUCA_MOUSE (Q9WUM5) Succinyl-CoA ligase [GDP-forming] subunit alpha</td>
<td>NT&lt;sub&gt;k&lt;/sub&gt;IIcQGFTGR</td>
<td>0.853</td>
<td>0.073</td>
<td>0.530</td>
<td>0.048</td>
<td>0.621</td>
<td>0.02</td>
</tr>
<tr>
<td>7</td>
<td>THIL_MOUSE (Q8QZT1) Acetyl-CoA acetyltransferase</td>
<td>VL&lt;sub&gt;y&lt;/sub&gt;AGL&lt;sub&gt;K&lt;/sub&gt;</td>
<td>0.955</td>
<td>0.025</td>
<td>0.459</td>
<td>0.178</td>
<td>0.481</td>
<td>0.05</td>
</tr>
<tr>
<td>8</td>
<td>VDAC1_MOUSE (Q60932) Voltage-dependent anion-selective channel protein 1</td>
<td>LTFDSSFSPNTG&lt;sub&gt;k&lt;/sub&gt;K</td>
<td>0.923</td>
<td>0.041</td>
<td>0.658</td>
<td>0.032</td>
<td>0.713</td>
<td>0.02</td>
</tr>
<tr>
<td>9</td>
<td>VDAC2_MOUSE (Q60930) Voltage-dependent anion-selective channel protein 2</td>
<td>YKWeEYGLT&lt;sub&gt;F&lt;/sub&gt;T&lt;sub&gt;TEK&lt;/sub&gt;</td>
<td>1.035</td>
<td>0.021</td>
<td>0.717</td>
<td>0.080</td>
<td>0.693</td>
<td>0.02</td>
</tr>
<tr>
<td>10</td>
<td>VDAC3_MOUSE (Q60931) Voltage-dependent anion-selective channel protein 3</td>
<td>cNTPTYcDLG&lt;sub&gt;k&lt;/sub&gt;A&lt;sub&gt;A&lt;/sub&gt;K</td>
<td>0.992</td>
<td>0.068</td>
<td>0.715</td>
<td>0.053</td>
<td>0.720</td>
<td>0.03</td>
</tr>
</tbody>
</table>

Relative quantification of acetylated peptides were performed using QUOIL (QUantification with OUT Isotope Labeling), an in-house software program designed as a label-free approach to peptide quantification by LC-MS/MS. The following criteria were used to determine the effect of chronic or acute inhibition of CypD on acetylated peptides: at least greater than 20% change and p <0.05 vs. WT samples. Accession numbers are from the SWISSPROT/Uniprot database. The acetylated lysine residue is in bold and italicized. SE, standard error; p, p-value.
Table 3. Acetylated proteins from electron transport chain complexes with increased in acetylation in the CypD−/− mitochondria.

<table>
<thead>
<tr>
<th>#</th>
<th>Accession</th>
<th>Protein ID</th>
<th>Protein Name</th>
<th># of acetylated peptides</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>AT5F1</td>
<td>Q9CQQ7</td>
<td>ATP synthase subunit b</td>
<td>4</td>
</tr>
<tr>
<td>2</td>
<td>ATP5H</td>
<td>Q9DCX2</td>
<td>ATP synthase subunit d</td>
<td>6</td>
</tr>
<tr>
<td>3</td>
<td>ATP5J</td>
<td>P97450</td>
<td>ATP synthase-coupling factor 6</td>
<td>4</td>
</tr>
<tr>
<td>4</td>
<td>ATP5L</td>
<td>Q9CPQ8</td>
<td>ATP synthase subunit g</td>
<td>3</td>
</tr>
<tr>
<td>5</td>
<td>ATP8</td>
<td>P03930</td>
<td>ATP synthase protein 8</td>
<td>2</td>
</tr>
<tr>
<td>6</td>
<td>ATPB</td>
<td>P56480</td>
<td>ATP synthase subunit beta</td>
<td>3</td>
</tr>
<tr>
<td>7</td>
<td>ATPG</td>
<td>Q91VR2</td>
<td>ATP synthase subunit gamma</td>
<td>1</td>
</tr>
<tr>
<td>8</td>
<td>ATPK</td>
<td>Q03265</td>
<td>ATP synthase subunit f</td>
<td>1</td>
</tr>
<tr>
<td>9</td>
<td>ATPO</td>
<td>Q9DB20</td>
<td>ATP synthase subunit O</td>
<td>4</td>
</tr>
<tr>
<td>10</td>
<td>COX5B</td>
<td>P19536</td>
<td>Cytochrome c oxidase subunit 5B</td>
<td>2</td>
</tr>
<tr>
<td>11</td>
<td>COX7C</td>
<td>P17665</td>
<td>Cytochrome c oxidase subunit 7C</td>
<td>1</td>
</tr>
<tr>
<td>12</td>
<td>CX7A1</td>
<td>P56392</td>
<td>Cytochrome c oxidase subunit 7A1</td>
<td>1</td>
</tr>
<tr>
<td>13</td>
<td>CYC</td>
<td>P62897</td>
<td>Cytochrome c, somatic</td>
<td>1</td>
</tr>
<tr>
<td>14</td>
<td>NDUAA</td>
<td>Q9CPP6</td>
<td>NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5</td>
<td>2</td>
</tr>
<tr>
<td>15</td>
<td>NDUAD</td>
<td>Q99LC3</td>
<td>NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10</td>
<td>1</td>
</tr>
<tr>
<td>16</td>
<td>NDUAD</td>
<td>Q9ERS2</td>
<td>NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13</td>
<td>1</td>
</tr>
<tr>
<td>17</td>
<td>NDUV1</td>
<td>Q91YT0</td>
<td>NADH dehydrogenase [ubiquinone] flavoprotein 1</td>
<td>2</td>
</tr>
<tr>
<td>18</td>
<td>QCR1</td>
<td>Q9CZ13</td>
<td>Cytochrome b-c1 complex subunit 1</td>
<td>1</td>
</tr>
<tr>
<td>19</td>
<td>QCR7</td>
<td>Q9D855</td>
<td>Cytochrome b-c1 complex subunit 7</td>
<td>3</td>
</tr>
</tbody>
</table>

Relative quantification of acetylated peptides were performed using QUOIL (QUantification withOUt Isotope Labeling), an in-house software program designed as a label-free approach to peptide quantification by LC-MS/MS. The following criteria were used to determine the effect of ablation of CypD on acetylated peptides: at least greater than 20% change and p <0.05 vs. WT samples. Accession numbers are from the SWISSPROT/Uniprot database.
NOVELTY AND SIGNIFICANCE

What Is Known?

- Loss of Cyclophilin D (CypD) leads to a decrease in the ratio of fatty acid oxidation relative to glucose oxidation.

- Lysine acetylation has recently emerged as an important post-translational protein modification in the regulation of mitochondrial metabolism.

What New Information Does This Article Contribute?

- Identification of the cardiac mitochondrial acetylome.

- Loss of CypD results in changes to the cardiac mitochondrial acetylome, with the majority of proteins showing an increase in acetylation.

- Acetylation of the mitochondrial trifunctional protein subunit alpha leads to the inhibition of its activity.

We examined whether CypD regulates mitochondrial metabolism by modulating changes in protein acetylation. We used a mass spectrometry-based approach and identified acetylated proteins in cardiac mitochondria under baseline conditions. We then compared differences in protein acetylation profiles in heart mitochondria from WT mice and mice lacking CypD. We found a general increase in mitochondrial protein acetylation in CypD-null hearts including several protein targets involved in fatty acid oxidation. A further examination of one of these protein targets, trifunctional protein subunit alpha, showed that acetylation leads to the inhibition of enzyme activity. This study provides an important link between acetylation and mitochondrial function, and suggests that the mitochondrial acetylome represents a new layer of protein regulation mediating adaptive changes in mitochondrial metabolism.
Figure 1

A

WT  CypD−/−

220

120

80

60

40

30

20

100

60

50

40

30

20

Anti-acetylated lysine

B

Densitometry (Arbitrary Unit)

WT  CypD−/−

p = 0.0101 *

C

IP: Ac-K

IB: GRP75

Input

ATPA

Input

ODPA

Input

CypD

Input

WT  KO

Figure 1
Protein Levels

WT  CypD−/
100  200  9

Peptide Levels

WT  CypD−/
45   875  35

Figure 2a
Figure 2C
Figure 2D
Figure 3
Figure 4
Figure 5

A

Free Ca$^{2+}$

B

nmol Ca$^{2+}$/mg protein

WT
WT + CsA
SIRT3$^{-/-}$
SIRT3 + CsA

- CsA
+ CsA
Cyclophilin D Modulates the Mitochondrial Acetylome
Tiffany Tuyen M Nguyen, Renee P Wong, Sara Menazza, Junhui Sun, Yong Chen, Guanghui Wang, Marjan Gucek, Charles Steenbergen, Michael N Sack and Elizabeth Murphy

Circ Res. published online September 23, 2013;
Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/early/2013/09/23/CIRCRESAHA.113.301867

Data Supplement (unedited) at:
http://circres.ahajournals.org/content/suppl/2013/09/23/CIRCRESAHA.113.301867.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org//subscriptions/
**SUPPLEMENTAL MATERIAL**

**Detailed Materials and Methods**

**Animals.** All animals were treated and cared for in accordance with the *Guide for the Care and Use of Laboratory Animals* [National Institutes of Health (NIH), Revised 2011], and protocols were approved by the Institutional Animal Care and Use Committee. Adult male and female CypD-WT (C57/BL6 background) and CypD-/- mice were kindly provided by Dr. Jeffery Molkentin University of Cincinnati, Children’s Hospital Medical Center as breeders. Male mice were between 12 to 16 weeks of age at the time of experimentation.

**Mitochondria Isolation.** Mitochondria were isolated by differential centrifugation according to standard procedures. Hearts were minced in mitochondrial isotonic buffer consisting of (in mmol/L): 225 mannitol, 75 sucrose, 5 MOPS, 0.5 EGTA, and 2 taurine (pH 7.25) plus 5 nicotinamide + 0.001 Trichostatin A (TsA) (Buffer B), and homogenized by Polytron. To digest the contractile proteins, trypsin (0.001 g/0.1 g wet tissue) in Buffer B was added to the homogenate for 5 min on ice. Digestion was stopped by addition of phosphatase and protease inhibitors (PPI). The homogenate was centrifuged at 500 g and the resulting supernatant was spun at 11,000 g to pellet the mitochondria. The final mitochondrial pellet was resuspended in Buffer B with PPI.

**Western blot.** Equivalent amounts of protein (20–40 µg) from each sample were separated on NuPAGE 4–12% Bis-Tris gels (Invitrogen, Carlsbad, CA) and transferred to nitrocellulose membranes. Gel transfer efficiency and equal loading were verified using reversible Ponceau S staining. The resulting blots were probed with anti-acetylated lysine antibody (Cell Signaling, Danvers, MA), anti-GCN5L1, anti-SIRT3, anti GRP75, anti-VDAC-1 (Santa Cruz Biotechnology), anti- pyruvate dehydrogenase E1 component subunit alpha (ODPA), anti F1Fo ATP synthase α subunit, or Cyclophilin D antibody (Mitosciences, Eugene, Oregon).

**Immunoprecipitation (IP) for acetylated proteins.** Isolated mitochondria (500 µg) were lysed in ice-cold mitochondrial IP buffer [1% n-dodecyl-b-D-maltoside, 0.5 mmol/L EDTA, 150 mmol/L NaCl, 50 mmol/L Tris–HCl, (pH 7.4), 10 mmol/L nicotinamide, 500 µmol/L trichostatin A and proteinase/phosphatase inhibitor]. The lysates were centrifuged for 10 min at 10,000g, 4°C, Anti-acetyllysine antibody was added to the lysate and incubated overnight at 4°C with shaking. The mitochondrial lysate is then incubated with Protein A/G agarose beads (Santa Cruz Biotechnology) for 2 h at 4°C with shaking. These samples were washed 2X with IP buffer then 3X with PBS. The bound proteins were eluted with the SDS-PAGE loading buffer by heating at 95°C for 5 min. Eluted samples were then continued to Western blot analyses using anti-GRP75, anti-F1Fo ATP synthase subunit A (ATPA), anti- pyruvate dehydrogenase E1 component subunit alpha (ODPA) antibodies.

**Affinity Purification of Lysine-Acetylated Peptides for Mass Spectrometry.** Isolated mitochondrial pellets (1 mg) were resuspended in 8 M guanidine hydrochloride solution (Sigma, St. Louis, MO). The samples were reduced with 5 mM dithiothreitol in 25 mM triethylammonium bicarbonate (TEA-Bic, Sigma) for 1 hr at 60°C and then alkylated using 15 mM iodoacetamide for 30 mins at 37°C in the dark. The reaction was quenched with DTT. Afterwards, the samples were diluted 8X with 25 mmol/L TEA-Bic buffer to a concentration guanidine hydrochloride <1M.

The samples were then digested with trypsin (protein enzyme ratio of approximately 50:1) overnight at 37°C. The tryptic peptides were acidified using formic acid and desalted on Oasis HLB 1 cm³ cartridges (Waters, Milford, MA) per manufacturer’s instructions. Collected eluents were lyophilized overnight and resolubilized in NETN buffer (in mmol/L) (50 Tris-HCl [pH 8.0], 100 NaCl, 1 EDTA, 0.5% NP40). Tryptic peptides were enriched by immunoprecipitation using agarose beads-coupled to anti-acetyl lysine antibody (Immunechem, Burnaby British Columbia, Canada) as described previously.
Briefly, the digested crude peptides were incubated with anti-acetyl lysine-coupled agarose beads overnight at 4°C with gentle shaking. The beads were washed 3X with 1 ml of NETN buffer then 2X with ETN buffer (in mmol/L: 50 Tris-HCl [pH 8.0], 100 NaCl, 1 EDTA). The bound acetylated peptides were eluted from the beads by washing 3X with 0.1% TFA. The eluates were combined and dried completely. The samples were analyzed on an LTQ Orbitrap Velos (Thermo Fisher Scientific, San Jose, CA) coupled with an Eksigent nanoLC-Ultra 1D plus system (Dublin, CA). Peptides were separated on a PicoFrit analytical column (100mm long, ID 75 μm, tip ID 10 μm, packed with BetaBasic 5 μm 300 Å particles, New Objective, Woburn, MA) using a 160-min linear gradient of 5-35% ACN in 0.1% FA at a flow rate of 250 nL/min. Mass analysis was carried out in data-dependent analysis mode, where MS1 scanned full MS mass range from m/z 300 to 2000 at 30,000 mass resolution and 10 CID MS2 scans were sequentially carried out in the Orbitrap and the ion trap, respectively.

The LCMS data were searched against the Swiss Prot database, taxonomy Mus (mouse) using Mascot server (Matrix Science, London, UK; version 2.3). Searching parameters were set as follow: precursor mass tolerance at 20 ppm, fragment ion mass tolerance at 0.8 Da, trypsin enzyme with 4 miscleavages, methyl carbamidomethylation of cysteine as fixed modification, and deamidation of asparagine and glutamine, oxidation of methionine, and acetylation of lysine as variable modifications. Peptides were filtered with 0.01 false discovery rate (FDR). Relative quantification of acetylated peptides were performed using QUOIL (Quantification withOut Isotope Labeling), an in-house software program designed as a label-free approach to peptide quantification by LC-MS/MS 2.

**Langendorff heart perfusion protocol.** Mice were anesthetized with an intraperitoneal injection of 0.10 cc pentobarbital sodium diluted 1:5 in perfusate. The abdominal cavity was exposed with a transverse incision and 0.05 cc heparin was administered to the inferior vena cava. The heart was quickly isolated and placed in ice-cold Krebs-Heinseleit (KH) buffer (in mmol/L: 25 NaHCO3, 120 NaCl, 11 glucose, 4.7 KCl, 1.2 KH2PO4, 1.2 MgSO4, and 1.75 CaCl2) to arrest the heart. The aorta was cannulated on a Langendorff apparatus and the heart was perfused in retrograde fashion with KH buffer at a constant pressure of 100 cm of water at 37°C. All hearts were perfused with KH buffer gassed with 95% O2 and 5% CO2.

**Myocyte Isolation.** Adult mouse ventricular cardiomyocytes were isolated by a modified perfusion method as previously described 3. Briefly, hearts were excised from mice anesthetized with sodium pentobarbital. Using a Langendorff apparatus, hearts were perfused with Ca2+-free Tyrode’s buffer (mmol/L): 140 NaCl, 4 KCl, 1 MgCl2, 5 HEPES, pH 7.4, 10 D-glucose, bubbled with 100% O2 for 5 min at 37°C. Perfusion was then switched to the Tyrode’s buffer containing 0.1 mmol/L CaCl2 and Liberase Blendzyme 2 (Roche Diagnostics, Cat#11988425001). Hearts were digested until the flow rate increased to 1.5 fold. After perfusion/digestion, the ventricular tissue was minced, gently triturated and incubated in 5 ml of same digestion buffer for 3 min at 37°C; the dissociated myocytes were transferred into an equal volume of the Tyrode’s buffer containing 0.2 mmol/L CaCl2 and 10 mg/ml bovine serum albumin (Sigma, Cat#A6003) to stop the digestion. This process was repeated three times. After gradually increasing CaCl2 to 1.2 mmol/L, the isolated cardiomyocytes were suspended into modified MEM buffer containing 100 U/ml penicillin-streptomycin. The cardiomyocytes were attached to matrigel-coated coverslips for 30 min in a 5% CO2 incubator at 37°C in medium 199 supplemented with 5 mmol/L creatine, 2 mmol/L L-carnitine, 5 mmol/L taurine, 2.5 mmol/L sodium pyruvate, 26 mmol/L NaHCO3, 100 U/mL penicillin, and 100 μg/mL streptomycin.

**Mitochondrial NADH Measurement.** Myocytes were mounted on the stage of a fluorescence microscope (Nikon Diaphot) with a 20× objective and superfused with Tyrode’s solution (25°C) containing (mmol/L): 140 NaCl, 4 KCl, 1 MgCl2, 5 HEPES, and 10 D-glucose (pH 7.4). The endogenous mitochondrial NADH fluorescence was excited at λex= 340 nm (band pass filter) and its emission recorded at λem = 415 nm (long pass filter) into a QuantEM 512 SC electron-multiplying charge-
coupled device (CCD) camera (Photometrics, Tucson, AZ). NADH levels were expressed as a percent of the reduced NADH/NAD⁺ pool, which was calibrated by applying 4 mmol/L NaCN (100%) and 5 μmol/L carbonyl cyanide 3-chlorophenyl hydrazone (CCCP) (0%) for each experiment.

Mitochondrial swelling and calcium retention capacity assays. Mitochondrial permeability transition pore opening in isolated heart mitochondria from WT and CypD⁻/⁻ mouse hearts was assessed using the calcium retention capacity assay (CRC) and Ca²⁺-induced swelling assay. Mitochondria were suspended in swelling buffer (in mmol/L: 120 KCl, 10 Tris-HCl, 5 MOPS, 5 Na₂HPO₄, 10 glutamate, and 2 malate) in a total volume of 200 μl for both assays. CRC was assessed using 10 μmol/L of the fluorescent Ca²⁺ indicator, Calcium Green-5N (Molecular Probes, Eugene, OR) with the addition of 10 μmol/L Ca²⁺ pulses to induce mPTP opening. Ca²⁺-induced swelling assay was measured spectrophotometrically as a decrease in absorbance at 540 nm after pore opening was induced by 250 μmol/L of CaCl₂. Both assays were assessed in the presence and absence of 200 nmol/L cyclosporine A (CsA), a known mPTP inhibitor.

Statistical Analysis. All data were expressed as mean ± S.E. The student’s 2-sample t-test or one-way ANOVA with Bonferroni’s post hoc analyses were used for comparison of differences between groups and a p-value ≤ 0.05 was considered to be significant.

SUPPLEMENTAL REFERENCES

Online Table Legends

**Online Table I. Profile of acetylated protein at baseline.** Acetylated proteins were identified using mass spectrometry using Proteome Discover software. To be included, peptide(s) must be identified in at least two out of three biological replicate samples.

**Online Table II. All acetylated peptide sequences identified via proteomic analysis that are present in the WT and CypD\(^{-}\) mitochondria.** All acetylated proteins were identified using mass spectrometry using Proteome Discover software in 3 biological replicates using the same criteria as specified in figure legend 2A. Potential SIRT3 substrates are bolded.

**Online Table III. Acetylated peptide sequences identified via proteomic analysis that are identified only in the WT mitochondria.** Peptides were identified using mass spectrometry using Proteome Discover software. A peptide must be present in 2 out of 3 replicates in the WT samples and not present in any of the KO in order to be included in the WT only group. Potential SIRT3 substrates are bolded. Accession numbers are from the SWISSPROT/Uniprot database.

**Online Table IV. Acetylated peptide sequences identified via proteomic analysis that are identified only in the CypD\(^{-}\) mitochondria.** Peptides were identified using mass spectrometry using Proteome Discover software. A peptide must be present in 2 out of 3 replicates in the KO samples and not present in any of the WT in order to be considered in the KO only group. Potential SIRT3 substrates are bolded. Accession numbers are from the SWISSPROT/Uniprot database.

**Online Table V. Acetylated peptide sequences identified via proteomic analysis that were increased in acetylation in the CypD\(^{-}\) mitochondria.** Relative quantification of acetylated peptides were performed using QUOIL (QUantification withOut Isotope Labeling), an in-house software program designed as a label-free approach to peptide quantification by LC-MS/MS. The following criteria were used to determine the effect of ablation of CypD on acetylated peptides: at least greater than 20% change and p <0.05 vs. WT samples. Potential SIRT3 substrates are bolded. Accession numbers are from the SWISSPROT/Uniprot database. SE, standard error; p, p-value.

**Online Table VI. Identified SIRT3 potential substrates.** All identified acetylated peptides that are increase in acetylation in SIRT3\(^{-}\) hearts compared to WT littermates.
Online Figure Legends

**Online Figure I. Alterations in canonical pathways based on changes in acetylation in CypD−/− hearts.** The canonical pathways associated with an increase in acetylation in CypD−/− mitochondria were analyzed using Ingenuity Pathway Analysis to identify specific key signaling pathways that might be targeted by upregulation of acetylation.

**Online Figure II. Hypothesis of increase in mitochondrial acetylome by loss of CypD.** Loss of CypD leads to transient inhibition of mPTP, an increase in matrix Ca^{2+} and activation of mitochondrial dehydrogenases (e.g. PDH), elevation of NADH/NAD^{+} levels. This results in an inhibition of mitochondrial deacetylase activity and subsequently increases in protein acetylation.
Online Figure I. Alterations in canonical pathways based on changes in acetylation in CypD−/− hearts. The canonical pathways associated with an increase in acetylation in CypD−/− mitochondria were analyzed using Ingenuity Pathway Analysis to identify specific key signaling pathways that might be targeted by upregulation of acetylation.
Online Figure II. Hypothesis of increase in mitochondrial acetylome by loss of CypD. Loss of CypD leads to transient inhibition of mPTP, an increase in matrix Ca$^{2+}$ and activation of mitochondrial dehydrogenases (e.g. PDH), elevation of NADH/NAD$^+$ levels. This results in an inhibition of mitochondrial deacetylase activity and subsequently increases in protein acetylation.